Melinta Therapeutics and Menarini Group Enter Commercial Agreement

Melinta Therapeutics (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, and Menarini Group, an Italian biopharmaceutical group, today announced that they have entered into an agreement under which Menarini will acquire the exclusive rights to co-develop and commercialize Vabomere™ (meropenem and vaborbactam), Orbactiv (oritavancin) and Minocin (minocycline) for Injection in 68 countries in Europe, Asia-Pacific including China, South Korea, and Australia (Japan excluded), and the Commonwealth of Independent States (CIS) including Russia for a total consideration of up to $265 million.

As quoted in the press release:

Melinta will maintain its rights for Vabomere, Orbactiv and Minocin for Injection in the U.S., where all three products are currently marketed.

A marketing authorization application for Vabomere is currently under review by the EMA. On September 20, 2018, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Vabomere, intended for the treatment of complicated intra-abdominal and urinary tract infections, hospital-acquired pneumonia, bacteraemia that occurs in association with any of these infections and infections due to aerobic Gram-negative organisms where treatment options are limited. Orbactiv is approved by the EMA for the treatment of adults with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible designated gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA).

Click here to read the full press release.